Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view

Urologia Internationalis

Volumn 63, Issue 1, 1999, Pages 16-21

  Mickisch, Gerald H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Metastatic renal cancer; Overview; Surgical therapy

Indexed keywords

IMMUNOMODULATING AGENT;

CANCER IMMUNOTHERAPY; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0032742533     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030413     Document Type: Review

References (18)

1. Scheltema JMW. Mickisch GH: Management of metastatic renal cell carcinoma: Role of nephrectomy, immunotherapy, failure of chemotherapy and drug resistance. Eur Urol Update Ser 1997;6:27-33.
2. Mickisch GH: No touch nephrectomy: Still a necessity? Eur Urol Update Ser 1998;7:115-117.
3. De Riese W, Goldenberg K, Allhoff E, et al: metastatic renal cell carcinoma: Spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 1991;23:13-25.
4. Oliver RTD: Surveillance as a possible option for management of metastatic renal cell carcinoma. Semin Urol 1989;7:149-152.
5. Franklin JR, Figlin R, Belldegrun A: Renal cell carcinoma: Basic biology and clinical behavior. Semin Urol Oncol 1996;14:208-215.
6. Joffe JK, Banks RE, Forbes MA, et al: A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: Clinical data and laboratory evidence of protease activation. Br J Urol 1996;77:638-649.
7. Van Poppel H, Baert L: Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 1996;64:11-17.
8. Kavolius JP, Mastorakos DP, Pavlovich C, et al: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-2266.
9. O'Connell JR, McCaffrey JA, Motzer RJ, et al: What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996;23:17-28.
10. Walther MM, Yang JC, Pass HI, et al: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997;158:1675-1678.
11. Bennett RT, Lerner SE, Taub HC, et al: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154:32-34.
12. Taneja SS, Pierce W, Figlin R, et al: Immunotherapy for renal cell carcinoma: the era of interleukin-2 based treatment. Utology 1995; 45:911-914.
13. Fallick ML, McDermott DF, LaRock D, et al: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997;158:1691-1695.
14. Fleischmann JD, Kim B: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991;145:938-941.
15. Rackley R, Novick AC, Klein EA, et al: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994;152:1399-1403.
16. Krishnamurthi V, Novick AC, Bukowski RM: Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 1998;51:933-937.
17. Bukowsky RM: Natural history and therapy of metastatic renal cell carcinoma. Cancer 1997; 80:1198-1220.
18. Hänninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institutional patients. J Urol 1996;155:19-25.